ID

31396

Descripción

MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918); ODM derived from: https://clinicaltrials.gov/show/NCT01028586

Link

https://clinicaltrials.gov/show/NCT01028586

Palabras clave

Versiones (1)
  1. 19/8/18 19/8/18 -
Titular de derechos de autor

see clinicaltrials.gov

Subido en

19 de agosto de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

  • El más nuevo
  • Más antiguo
  • Popular
  • El más nuevo
    • El más nuevo
    • Más antiguo
    • Popular

Sin comentarios

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Idiopathic Parkinson's Disease NCT01028586

Inglés

Eligibility Idiopathic Parkinson's Disease NCT01028586

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. the subject completed 24 weeks of trial 27918.
Descripción

Completion of clinical trial

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2732579
2. the subject successfully completed all trial requirements in trial 27918.
Descripción

Clinical Trials; Requirement; Complete

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0008976
UMLS CUI [1,2]
C1514873
UMLS CUI [1,3]
C0205197
3. if female, they must be either post menopausal for at least 2 years, surgically sterilized or have undergone hysterectomy or, if of child bearing potential they must be willing to avoid pregnancy by using an adequate method of contraception as defined in the protocol for four weeks prior to, during and four weeks after the last dose of trial medication. for the purposes of this trial, women of childbearing potential are defined as: "all female subjects after puberty unless they are post-menopausal for at least two years, are surgically sterile or are sexually inactive".
Descripción

Postmenopausal state; Duration (temporal concept) | Female Sterilization | Hysterectomy | Contraceptive methods | Childbearing Potential

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0232970
UMLS CUI [1,2]
C0449238
UMLS CUI [2]
C0015787
UMLS CUI [3]
C0020699
UMLS CUI [4,1]
C1960468
UMLS CUI [4,2]
C0700589
UMLS CUI [4,3]
C0449238
UMLS CUI [5,1]
C3831118
UMLS CUI [5,2]
C0429595
UMLS CUI [5,3]
C0232970
UMLS CUI [5,4]
C0449238
UMLS CUI [5,5]
C0021359
UMLS CUI [5,6]
C0241028
4. subject is willing and able to participate in the trial and has provided written, informed consent
Descripción

Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. if female, the subject is pregnant or lactating.
Descripción

Pregnancy | Breast Feeding

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
2. the subject experienced a clinically significant adverse effect during trial 27918 that could put the subject at risk according to the investigator's opinion.
Descripción

Adverse event; Significant; Time | Risk | Clinical Investigators; Opinions

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0877248
UMLS CUI [1,2]
C0750502
UMLS CUI [1,3]
C0040223
UMLS CUI [2]
C0035647
UMLS CUI [3,1]
C0008961
UMLS CUI [3,2]
C0871010
3. the subject has shown clinically significant deterioration during participation in trial 27918.
Descripción

Deterioration of status; Significant; Time

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1279889
UMLS CUI [1,2]
C0750502
UMLS CUI [1,3]
C0040223
4. motor deterioration during trial 27918 that required upward titration of existing anti-parkinsonian medication or the initiation of an additional anti-parkinsonian medication.
Descripción

Motor deterioration; Time | Antiparkinson Agents; Titration Method

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1866284
UMLS CUI [1,2]
C0040223
UMLS CUI [2,1]
C0003405
UMLS CUI [2,2]
C0162621
5. the investigator deems it is not in the subject's best interest to participate to trial 27938
Descripción

Conflict of Interest

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0079152
6. signs and symptoms suggestive of transmissible spongiform encephalopathy, or family members who suffer(ed) from such.
Descripción

Transmissible spongiform encephalopathy | Brain; Signs and Symptoms; Suggestive of Unit

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3700367
UMLS CUI [1,2]
C0037088
UMLS CUI [1,3]
C0332299
Volver a la parte superior de la página

Similar models

Eligibility Idiopathic Parkinson's Disease NCT01028586

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Completion of clinical trial
Item
1. the subject completed 24 weeks of trial 27918.
boolean
C2732579 (UMLS CUI [1])
Clinical Trials; Requirement; Complete
Item
2. the subject successfully completed all trial requirements in trial 27918.
boolean
C0008976 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])
Postmenopausal state; Duration (temporal concept) | Female Sterilization | Hysterectomy | Contraceptive methods | Childbearing Potential
Item
3. if female, they must be either post menopausal for at least 2 years, surgically sterilized or have undergone hysterectomy or, if of child bearing potential they must be willing to avoid pregnancy by using an adequate method of contraception as defined in the protocol for four weeks prior to, during and four weeks after the last dose of trial medication. for the purposes of this trial, women of childbearing potential are defined as: "all female subjects after puberty unless they are post-menopausal for at least two years, are surgically sterile or are sexually inactive".
boolean
C0232970 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
C0015787 (UMLS CUI [2])
C0020699 (UMLS CUI [3])
C1960468 (UMLS CUI [4,1])
C0700589 (UMLS CUI [4,2])
C0449238 (UMLS CUI [4,3])
C3831118 (UMLS CUI [5,1])
C0429595 (UMLS CUI [5,2])
C0232970 (UMLS CUI [5,3])
C0449238 (UMLS CUI [5,4])
C0021359 (UMLS CUI [5,5])
C0241028 (UMLS CUI [5,6])
Informed Consent
Item
4. subject is willing and able to participate in the trial and has provided written, informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Pregnancy | Breast Feeding
Item
1. if female, the subject is pregnant or lactating.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Adverse event; Significant; Time | Risk | Clinical Investigators; Opinions
Item
2. the subject experienced a clinically significant adverse effect during trial 27918 that could put the subject at risk according to the investigator's opinion.
boolean
C0877248 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,3])
C0035647 (UMLS CUI [2])
C0008961 (UMLS CUI [3,1])
C0871010 (UMLS CUI [3,2])
Deterioration of status; Significant; Time
Item
3. the subject has shown clinically significant deterioration during participation in trial 27918.
boolean
C1279889 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,3])
Motor deterioration; Time | Antiparkinson Agents; Titration Method
Item
4. motor deterioration during trial 27918 that required upward titration of existing anti-parkinsonian medication or the initiation of an additional anti-parkinsonian medication.
boolean
C1866284 (UMLS CUI [1,1])
C0040223 (UMLS CUI [1,2])
C0003405 (UMLS CUI [2,1])
C0162621 (UMLS CUI [2,2])
Conflict of Interest
Item
5. the investigator deems it is not in the subject's best interest to participate to trial 27938
boolean
C0079152 (UMLS CUI [1])
Transmissible spongiform encephalopathy | Brain; Signs and Symptoms; Suggestive of Unit
Item
6. signs and symptoms suggestive of transmissible spongiform encephalopathy, or family members who suffer(ed) from such.
boolean
C3700367 (UMLS CUI [1,1])
C0037088 (UMLS CUI [1,2])
C0332299 (UMLS CUI [1,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial